Document:

EX-10.1

 Exhibit 10.1 

AMENDMENT OF 
 EXECUTIVE
EMPLOYMENT AGREEMENT 
 AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENT dated as of May 6, 2014, between The Boeing Company, a
Delaware corporation (the “Company”), and W. James McNerney, Jr. (the “Executive”). 
 W I T
N E S S E T H: 
 WHEREAS, the Company and the Executive entered into an employment agreement dated as of March 13, 2008
(the “Agreement”); 
 WHEREAS, the Company and the Executive desire to amend the Agreement so as to reflect the
impact of certain changes to the Company’s retirement benefit programs on the Executive’s supplemental retirement benefits as provided under the Agreement; 

NOW THEREFORE, in consideration of the foregoing and of other good and valuable consideration, the receipt and sufficiency of which are
hereby acknowledged, the parties hereto hereby agree: 
 1. To amend the Agreement by substituting the following for
Section 6(b) thereof in its entirety: 
 “(b) SUPPLEMENTAL RETIREMENT BENEFIT. Notwithstanding any provision of this
Agreement to the contrary, in the event that the Company ceases benefit accruals for employees under the plans covered by (iv)(A) below effective as of December 31, 2015, benefits under the Executive’s Supplemental Pension as defined and
described below in this Section 6(b) will cease to accrue under this Agreement as of December 31, 2015, meaning that the Executive’s Hypothetical Prior Employment Pension Benefits shall not be credited with compensation earned for
periods after December 31, 2015 for purposes of computing a benefit under this Section 6(b), including Sections 6(b)(iv)(E) and (F). The Executive specifically agrees that this cessation of benefit accruals under the Executive’s
Supplemental Pension shall not be a violation of Section 6(a) nor ‘Good Reason’ as defined in Section 7(e). 

(i) The Executive will receive a supplemental pension benefit (‘Supplemental Pension’) in an amount equal to
(A) the Hypothetical Prior Employer Pension Benefits, minus (B) the sum of the Actual Company Pension Benefits, Actual Prior Employer Pension Benefits, and benefits paid or payable to the Executive under any other employer’s qualified
and non-qualified defined benefit pension plan with respect to service prior to the Effective Date. If the remainder is zero or less, no amount shall be payable by the Company hereunder. 

(ii) The Supplemental Pension is fully vested. 

(iii) The Supplemental Pension will be payable as of the date of Executive’s Separation from Service or an earlier 409A
Change in Control (both such terms as hereinafter defined; and, for the avoidance of doubt, no further amount shall be payable upon any Separation from Service occurring after a 409A Change in Control), or

 
such later date as required under 409A, in a lump sum equal to the Actuarial Equivalent present value of an annuity, based on the accrued vested benefit due under the first sentence of
Section 6(b)(i), determined as of the date payment is due. If the Executive is a Specified Employee (as hereinafter defined) as of his Separation from Service, the Supplemental Pension shall be paid in a lump sum or payments will commence, as
provide herein, to the Executive on the date that is the first day of the seventh (7th) month after the date of his Separation from Service or, if earlier, the date of the Executive’s
death following such Separation from Service (with the amount of such Actuarial Equivalent lump sum (or other form of payment as may be provided, below) calculated as of such payment date as if such date was the date of Separation from Service) (the
‘Six-Month Delay Requirement’). In the event of a Separation from Service by reason of the Executive’s death or the Executive’s death after a Separation from Service but before payments under this Section 6(b)(iii),
the amount of such lump sum payment to the beneficiary designated by the Executive in writing to the Company during his lifetime (or, if no such beneficiary is designated, to the Executive’s estate) shall equal the lump sum payment that would
have been payable to the Executive if he had been alive on the date of payment. The Supplemental Pension benefit may, at the election of the Executive (made in accordance with 409A), also be paid in the form of a mutually agreeable commercially
available annuity, life insurance contract or such other Actuarially Equivalent mutually agreeable forms. The parties acknowledge that, prior to December 31, 2007, the Executive elected, and the Company agreed, to change the form of payment to
the form of fifteen (15) equal annual installments, by executing a mutually acceptable payment election form with the Company. Executive may elect to change the form of payment under this Section 6(b)(iii), by executing a mutually
acceptable payment election form with the Company, provided that, to the extent required by 409A and except as provided in the preceding sentence, such payment election form (A) shall be executed at least twelve (12) months prior to the
date payment was otherwise scheduled to be made, (B) shall not take effect until at least twelve (12) months after the date on which the election is made, and (C) shall specify a payment or payment commencement date that is at least
five (5) years after the date payment was otherwise scheduled to be made or commenced. 
 (iv) For purposes of this
Agreement, the terms set forth below have the following meanings: 
 (A) ‘Actual Company Pension Benefits’
means a single life annuity amount commencing at age sixty-two (62) and payable in monthly installments to the Executive for his life of the Actuarial Equivalent of the amounts that the Executive has actually received, or is entitled to
receive, from the Company’s qualified and non-qualified defined benefit pension plans. 
 (B) ‘Actual Prior
Employer Pension Benefits’ means a single life annuity amount commencing at age sixty-two (62) and payable in monthly installments to the Executive for his life of the Actuarial Equivalent of the amounts that the Executive has actually
received, or is entitled to receive, from the Prior Employers’ qualified and non-qualified defined benefit pension plans. 

  
 2 

 (C) ‘Actuarial Equivalent’ of any amount shall be determined in
accordance with generally accepted actuarial principles using interest rate, mortality and other methods and assumptions that the Pension Benefit Guaranty Corporation (“PBGC”) would have used in determining the value of an immediate
annuity payment of benefits with regard to terminations of plans immediately prior to enactment of the Retirement Protection Act of 1994, or if such interest rate and mortality assumptions are no longer published by the PBGC, interest rate and
mortality assumptions determined in a manner as similar as practicable to the manner by which the PBGC’s interest rate and mortality assumptions were determined immediately prior to the PBGC’s cessation of publication of such assumptions.

 (D) ‘409A Change in Control’ means a Change of Control (as defined herein) that also constitutes a
change in the ownership or effective control of the Company or a sale of a substantial portion of the assets of the Company, in accordance with the requirements of Code Section 409A(a)(2)(A)(v) and Treas. Reg. §1.409A-3(i)(5) (or any
successor provision) thereunder. 
 (E) ‘Highest Average Annual Compensation’ means, subject to the lead
portion of this Section 6(b), the Executive’s average annual compensation for the three (3) consecutive calendar years out of the last ten (10) calendar years preceding his Separation from Service or Change of Control, as the
case may be, during which such average is the highest. For purposes of determining the Executive’s Highest Average Annual Compensation, compensation paid by the Company or the Prior Employers shall be taken into account to the same extent as
such compensation would have been taken into account for purposes of such determination under the General Electric Company qualified and non-qualified defined benefit pension plans as in effect on December 31, 2000 if such compensation were
with or paid by the General Electric Company. In addition, solely for purposes of calculating the Executive’s average annual compensation, in the event of an involuntary Separation from Service without Cause (as hereinafter defined) or a
Separation from Service for Good Reason (as hereinafter defined), in which the Executive is entitled to severance benefits under this Agreement, applicable Company plans or otherwise, the Executive shall be treated as having earned any severance
paid to the Executive ratably over the course of the period to which it relates (e.g., two (2) years for severance equal to two (2) years of base salary). 

(F) ‘Hypothetical Prior Employer Pension Benefits’ means a benefit payable in the form of a single life
annuity amount commencing at age 62 and payable in monthly installments for the Executive’s life equal to one-twelfth (1/12th) multiplied by fifty percent (50%) of the Executive’s Highest Average Annual Compensation. 

(G) The ‘Prior Employers’ means the 3M Corporation and the General Electric Company. 

  
 3 

 (H) ‘Separation from Service’ or ‘Separates from
Service’ means the Executive’s death, retirement or termination of employment from the Company and all subsidiaries and affiliates, within the meaning of 409A; provided, however, that the foregoing shall not, alone, include the
Executive’s service as a director of the Company or any of its subsidiaries or affiliates. For purposes of determining whether a Separation from Service has occurred, to the extent permitted by 409A, subsidiaries and affiliates of the Company
are only those included by using the language ’at least eighty percent (80%)’ to define the controlled group under Code Section 1563(a) in lieu of the fifty percent (50%) default rule stated in Treas. Reg. §1.409A-1(h)(3).
To the extent permitted by 409A, a ‘Separation from Service’ shall be deemed to include a reasonably anticipated permanent reduction in the level of services performed by the Executive, to less than fifty percent (50%) of the
average level of services performed by the Executive during the thirty-six (36)-month period immediately preceding such separation. 

(I) The Executive is a ‘Specified Employee’ if on the date of his Separation from Service he is a
“specified employee” within the meaning of 409A and Treas. Reg. §1.409A-1(i) (or any successor provision). For such purpose, the “specified employee” identification date shall be December 31, the ’specified
employee’ effective date shall be the April 1 following such December 31 and the seventy-five (75) top-paid officers of the Company (and its subsidiaries and affiliates, provided above) shall be treated as within the definition
of Specified Employee.” 
 2. As amended herein the Agreement shall remain in full force and effect. 

IN WITNESS WHEREOF, the parties hereto have executed this Amendment to the Agreement effective as of the date first written above. 

 

			
	THE BOEING COMPANY
		
	By:	 	/s/ Arthur D. Collins, Jr.
	Name:	 	Arthur D. Collins, Jr.
	Title:	 	Chairman of the Compensation Committee
	
	EXECUTIVE
	
	/s/ W. James McNerney, Jr.
	W. James McNerney, Jr.

  
 4EX-10.1

 Exhibit 10.1 
 CORCEPT THERAPEUTICS INCORPORATED 
 CONSULTING AGREEMENT 

This Agreement is made and entered into as of the 1st day of January, 2014 (the “Effective Date”) by and between Corcept Therapeutics Incorporated
(“Corcept”), a Delaware corporation located at 149 Commonwealth Drive, Menlo Park, CA 94025, and Robert L. Roe (“Consultant”), an individual, located at Palo Alto, CA 94304. 

Recital 

As part of its ongoing program of research, development and commercialization, Corcept desires to retain qualified individuals to advise
Corcept with respect to its strategy and implementation in these areas. In furtherance thereof, Corcept and Consultant desire to enter into this Agreement. 
 Agreement 
 In consideration of the foregoing and the mutual promises
contained in this Agreement, Consultant and Corcept hereby agree as follows: 
  

	1.	Engagement of Services 

The consulting services that are the subject of this Agreement (“Services”) are described in the attached Schedule 1. These
Services may be modified from time to time by Corcept having due regard for Consultant’s obligations and commitments. Consultant will perform the Services for Corcept in good faith and to the best of Consultant’s ability at places and
times agreeable to Corcept and Consultant. 
  

	2.	Compensation 

 In
consideration for the Services and the terms of this Agreement, Consultant shall be paid the following compensation: 
 Corcept
shall pay Consultant a fee of $2,800 per Consulting Day, payable monthly within thirty (30) days of receipt of the invoice. A Consulting Day shall be defined as a minimum eight hour day of Services. If Consultant works less than a full
Consulting Day, Consultant’s fee for that day shall be calculated at a rate of $350.00 per hour. Also, options to purchase Corcept common stock which Consultant received during his tenure as an employee of Corcept shall (i) if not yet
vested, continue to vest during the term of this Agreement at the rate set forth in the applicable option grants and (ii) if vested, shall remain exercisable until three years following the termination of this Agreement (including any
extensions or renewals of this Agreement to which the parties may agree in writing), or if earlier, the original expiration date of such options. 
  

	3.	Additional Activities 

(a) Consultant agrees that during the term of this Agreement, Consultant will not, directly or indirectly, either as an employee,
employer, consultant, agent, principal, partner, stockholder, corporate officer, director, or in any other individual or representative capacity, 

 
engage, participate in or perform services (“Non-Corcept Consultant Services”) for any business that is in competition with the business then being conducted or planned by Corcept. For
the avoidance of doubt, Consultant may disclose in writing any on-going or contemplated Non-Corcept Consultant Services to the Chief Executive Officer or Chief Financial Officer of Corcept, who shall promptly notify Consultant, in writing, whether
such services are or would be in competition with the business then being conducted or planned by Corcept. 
 (b) Consultant
agrees that during the term of this Agreement, and for a period ending one year after the date of termination of this Agreement, Consultant will not (i) induce any employee of Corcept to leave the employ of Corcept or (ii) solicit the
business of any client or customer of Corcept, other than on behalf of Corcept. 
 (c) If any restriction set forth in Sections
3(a) and 3(b) above is found by any court of competent jurisdiction to be unenforceable because it extends for too long a period of time or over too great a range of activities or in too broad a geographic area, it shall be interpreted to extend
only over the maximum period of time, range of activities or geographic area as to which it may be enforceable. 
  

	4.	Proprietary Information and Assignment 

 (a) Consultant understands that during the term of this Agreement Consultant may produce, obtain, make known or learn about certain information which has commercial value in the business in which Corcept
is engaged and which is treated by Corcept as confidential. This information may also have been created, discovered or developed by Corcept or otherwise received by Corcept from third parties subject to a duty to maintain the confidentiality of such
information (“Third Parties”). All such information, together with any Confidential Information disclosed under the January 1, 2014 Confidentiality and Nondisclosure Agreement between Corcept and Consultant, hereinafter called
“Proprietary Information,” includes Inventions (as defined in Section 5(a) below) and all other trade secrets, ideas, processes, programs, and all tangible and intangible information relating to formulations, products, processes,
know-how, designs, formulas, methods, developmental or experimental work, improvements, discoveries, pending or potential patent claims and any information derived therefrom, plans for research, new products, marketing and selling, business plans,
budgets and unpublished financial statements, licenses, prices and costs, suppliers and customers, and information regarding the skills and compensation of other employees or consultants of Corcept. 

(b) Consultant hereby acknowledges Corcept’s ownership of the Proprietary Information and Consultant hereby assigns to Corcept any
right, title or interest Consultant may have or acquire in any such Proprietary Information. At all times during the term of this Agreement and thereafter, Consultant will keep in strictest confidence and trust all Proprietary Information, and
Consultant will not use, reproduce, disclose, lecture upon or publish any Proprietary Information without the written consent of Corcept, except (i) as may be necessary in the ordinary course of performing the Services and (ii) as
permitted by agreement between Corcept and any Third Party in the case of property that is solely any such Third Party’s, unless Consultant is expressly authorized to act otherwise by Corcept. 

  
 2 

	5.	Inventions During the Term of Agreement 

 (a) All Inventions (as defined below) and all original works of authorship (including without limitation, computer code and the documentation and notes related thereto) made or conceived by Consultant
during the term of this Agreement shall be works made for hire and shall become and remain the sole and exclusive property of Corcept. Consultant shall promptly notify Corcept in writing of all Inventions and original works of authorship pertaining
to scientific, medical or business matters so conceived or made by Consultant. “Inventions” means any and all ideas and discoveries, including, without limitation, findings, reports, disclosures, developments, improvements,
concepts, processes, methods, formulas, compositions, procedures, algorithms, devices, drawings, specifications, models, source code, object code, software, diagrams, flow charts, techniques, articles and machines, as well as improvements thereof or
know-how related thereto, whether copyrightable or patentable or not, relating to the business or planned business of Corcept or person or business entity directly or indirectly controlled by or controlling Corcept or in which any of the aforesaid
have at least a 50% ownership interest. 
 (b) To the extent that ownership of such Inventions and original works of authorship
do not automatically vest in Corcept, Consultant agrees to and hereby assigns and transfers to Corcept Consultant’s entire right, title and interest in and to all Inventions, whether or not patent or copyright applications are filed thereon.
Consultant shall, at Corcept’s request and expense, promptly execute a written assignment to Corcept of title to any such Invention and Consultant shall preserve any such Invention as part of the Proprietary Information of Corcept. Consultant
also hereby assigns and transfers to, or as directed by, Corcept all right, title and interest in and to any and all Inventions, full title to which is required to be in the United States by a contract between Corcept and the United States or any of
its agencies. Consultant further agrees as to all Inventions to assist Corcept in every proper way and to execute those documents and take such acts as are reasonably requested by Corcept to obtain, sustain and from time to time enforce patents,
copyrights, and other rights and protections for the Inventions in the United States and any other country. 
 (c) In the event
Corcept is unable, after reasonable effort, to secure Consultant’s signature on any document needed to apply for or prosecute any patent, copyright, or other right or protection for an Invention, Consultant hereby irrevocably designates and
appoints Corcept and its duly authorized officers and agents as its agent and attorney-in-fact, to act for and on Consultant’s behalf to execute, verify and file any such applications and to do all other lawfully permitted acts to further the
prosecution and issuance of patents, copyrights, and other rights and protections thereon with the same legal force and effect as if executed by Consultant. 
  

	6.	No Unauthorized Use of Third Party Technology 

 Consultant represents that, except as may be specified in a schedule prepared, signed and delivered by Consultant at the time of signing this Agreement, Consultant has not brought and will not bring to
Corcept or use in the performance of the services any device, material, document, trade secret or the like of any third party that is not generally available to the public, unless Consultant has obtained express written authorization from such third
party for their possession and use, including those items listed in the schedule. 

  
 3 

	7.	No Conflicting Obligations 

(a) Consultant represents that Consultant’s performance of all the terms of this Agreement and the Services does not and will not
breach any agreement to keep in confidence any information of another entity that Consultant has acquired or may acquire in confidence or in trust prior to the date or during the term of this Agreement. 

(b) Consultant agrees to submit to Corcept any proposed publication which contains any discussion relating to Corcept or work performed
by Consultant for Corcept under this Agreement. Consultant further agrees that no such publication shall be made without the prior written consent of Corcept. 
  

	8.	Independent Contractor/Taxes. 

 Consultant is not an agent or employee of Corcept and is not authorized to act on behalf of Corcept. Except as required by a final determination by the Internal Revenue Service or state taxing authority
and upon due notice to the other party, Consultant and Corcept agree that they will each treat Consultant as an independent contractor for tax purposes and file all tax and information returns and pay all applicable taxes on that basis. 

 

	9.	Term and Termination 

 The
Agreement shall be in full force and effect through December 31, 2014. This Agreement may thereafter be extended only by written agreement of the parties. The obligations and liabilities of Corcept and Consultant may be earlier
terminated as follows: 
 (a) Upon thirty (30) days’ written notice by either Consultant or Corcept. 

(b) Immediately upon written notice by Corcept to Consultant in the event of a material breach by Consultant of any of the covenants
contained herein or misconduct by Consultant having a materially adverse effect on the business of Corcept. 
  

	10.	Effect of Termination 

Upon any termination of this Agreement, each party shall be released from all obligations and liabilities to the other occurring or
arising after the date of such termination, except that any termination of this Agreement shall not relieve Consultant of Consultant’s obligations under Sections 3, 4, 5, 6 and 7 hereof, nor shall any such termination relieve either party from
any liability arising from any breach of this Agreement. Upon termination of this Agreement for any reason, Consultant shall promptly deliver to Corcept all documents, notes, drawings, specifications, calculations, laboratory materials, data and
other materials of any nature pertaining to Consultant’s work with Corcept, and documents or data of any description (or any reproduction of any documents or data) containing or pertaining to any Proprietary Information. In the event of such
termination, Consultant shall cooperate with Corcept in completing and signing Corcept’s termination statement for Consultant. 

  
 4 

	11.	Legal and Equitable Remedies 

 Because Consultant’s services are personal and unique and because Consultant may have access to and become acquainted with Proprietary Information of Corcept, Corcept shall have the right to enforce
this Agreement and any of its provisions by injunction, specific performance or other equitable relief without prejudice to any other rights and remedies that Corcept may have for a breach of this Agreement. 

 

	12.	General Terms 

 (a) This
Agreement constitutes the final, complete and exclusive agreement between Corcept and Consultant, superseding any previous oral or written communication, representation, understanding or agreement, including the January 1, 2014
Confidentiality and Nondisclosure Agreement between the parties. 
 (b) This Agreement shall inure to the benefit of the
successors and assigns of Corcept, and shall be binding upon Consultant’s successors and permitted assigns. 
 (c) To the
extent that any part of this Agreement shall be found to be illegal or unenforceable for any reason, such part shall be modified or deleted in such a manner so as to make the Agreement legal and enforceable under applicable laws. 

(d) This Agreement shall be governed by the laws of the State of California, notwithstanding its conflict of laws principles. 

(e) This Agreement may not be amended, modified, released, discharged, abandoned, or otherwise changed, in whole or in part, except by a
written instrument signed by both parties. 
 (f) Any notices required or permitted hereunder shall be given to the appropriate
party at the address specified below or at such other address as the party shall specify in writing. Such notice shall be deemed given upon personal delivery, or sent by certified or registered mail, postage prepaid, three (3) days after the
date of mailing, to the appropriate address below. 
 (g) Corcept has specifically contracted for Consultant’s services,
Consultant shall not assign any of its rights or delegate any of its obligations under this Agreement without the prior written consent of Corcept. Any such attempted assignment or delegation without proper consent shall be void. 

(h) The waiver of any term or condition contained in this Agreement by any party to this Agreement shall not be construed as a waiver of
a subsequent breach or failure of the same term or condition or a waiver of any other term or condition contained in this Agreement. 

  
 5 

 IN WITNESS WHEREOF, the parties hereto have executed this Agreement as of the date first
written above. 
  

							
	CORCEPT THERAPEUTICS INCORPORATED	 	 Robert L. Roe

		 	(Name of Institution/Corporation/Vendor)
				
	Address:	 	 149 Commonwealth Drive

Menlo Park, CA 94025
	 	Address:	 	Palo Alto, CA 94304
		 		 		 	

							
				
	By:	 	 /s/ G. Charles Robb
	 	  By:	 	 /s/ Robert L. Roe

				
		 	 G. Charles Robb
	 		 	 Robert L. Roe

		 	(Print Name)	 		 	(Print Name)
				
		 	 Chief Financial Officer
	 		 	  

		 	(Title)	 		 	(Title)
				
		 	 1/7/14
 (Date)
	 		 	 07 – January - 2014
 (Date)

  
 6 

 Schedule 1 
 CONSULTING SERVICES 
 Consulting Services to be provided shall include
advice regarding clinical and pre-clinical development activities, interactions with the FDA and other regulatory bodies, general management consulting, assistance with the management of third-party clinical trials, the hiring and training of a
Chief Medical Officer and other personnel, and any other matters to which the parties may agree. 

  
 7

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00231-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00231-of-00352.parquet"}]]